AN 721

Drug Profile

AN 721

Alternative Names: AN-721; NSD-721

Latest Information Update: 04 Dec 2013

Price : $50

At a glance

  • Originator NeuroSearch
  • Developer Aniona; Saniona
  • Class Analgesics; Anxiolytics
  • Mechanism of Action GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain
  • Preclinical Inflammatory pain; Neuropathic pain
  • Discontinued Anxiety disorders

Most Recent Events

  • 04 Dec 2013 AN 721 is available for licensing as of 04 Dec 2013. http://www.aniona.com
  • 04 Dec 2013 Preclinical trials in Inflammatory pain in Denmark (unspecified route)
  • 04 Dec 2013 Preclinical trials in Neuropathic pain in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top